摘要
目的:探讨吉非替尼单药治疗晚期非小细胞肺癌(NSCLC)的疗效。方法:对54例晚期NSCLC患者给予吉非替尼250mg.d-1口服治疗,并获得随访的NSCLC患者资料,评价其疗效、生存质量及不良反应。结果:54例晚期NSCLC患者中,无完全缓解者,部分缓解9例(16.67%),临床受益率为61.11%,临床受益率与性别、病理类型、吸烟史有关。患者各项生存质量均明显改善率为14.81%。主要的不良反应为皮疹(48.15%)和腹泻(26.93%),对症治疗后缓解。结论:吉非替尼对NSCLC患者有较好的疗效和安全性,能明显提高患者的生活质量,改善临床症状。
OBJECTIVE To evaluate the efficacy of gefitinib in the treatment of patients with advanced non-small cell lung cancer（NSCLC）. METHODS Fifty-four advanced NSCLC patients were treated with gefitinib orally 250 mg once per day. And clinical data of 54 NSCLC cases were collected and analyzed. Evaluations were made about curative effects, quality of life and toxic reactions. RESULTS Even though none of these patients achieved complete response, 16. 67% of them still gave partial response. Clinical benefit rate was 61.11 % in this series. Objective tumor response was correlated with gender, patho logical type and smoking history. And alleviative rate of clinical symptoms in patents was 14. 81%. The main toxicities were reversible skin rash and diarrhea. CONCLUSION Gefitinib is effective and tolerated by the patients with advanced non-small cell lung cancer, h can improve their symptoms and quality of life obviously.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2008年第22期1943-1945,共3页
Chinese Journal of Hospital Pharmacy
关键词
吉非替尼
非小细胞肺癌
疗效
不良反应
gefitinib
non-small cell lung cancer
efficacy
adverse reaction
